

**Applicant:** Aurogen South Africa (Pty) Ltd

**Product Name:** MACRITIR

**Dosage form and strength:** **HARD GELATIN CAPSULE**, each capsule contains 50 mg and 100 mg Nitrofurantoin

**MODULE 1**

1.3.1.1

**1.3.1.1 Approved Professional Information for Medicines for Human Use (Approved)**

S NO		REFERENCE
	<p><b>SCHEDULING STATUS</b></p> <p><b>S4</b></p>	
	<p><b>1. NAME OF THE MEDICINE</b></p> <p><b>MACRITIR 50</b>, Hard gelatin capsules.</p> <p><b>MACRITIR 100</b>, Hard gelatin capsules.</p>	
	<p><b>2. QUALITATIVE AND QUANTITATIVE COMPOSITION</b></p> <p><b>MACRITIR 50:</b></p> <p>Each capsule contains 50 mg Nitrofurantoin</p> <p>For full list of excipients, see section 6.1.</p> <p>Contains: Sugar free</p> <p><b>MACRITIR 100:</b></p> <p>Each capsule contains 100 mg Nitrofurantoin</p> <p>For full list of excipients, see section 6.1.</p> <p>Contains: Sugar free</p>	
	<p><b>3. PHARMACEUTICAL FORM</b></p> <p><b>MACRITIR 50:</b></p> <p>Hard gelatin capsules of size '4' with white opaque body imprinted with '50' and yellow opaque cap imprinted with 'NMC' with black ink, filled with yellow to light yellow granular powder.</p> <p><b>MACRITIR 100:</b></p>	



**Applicant:** Aurogen South Africa (Pty) Ltd

**Product Name:** MACRIXITIR

**Dosage form and strength:** **HARD GELATIN CAPSULE**, each capsule contains 50 mg and 100 mg Nitrofurantoin

**MODULE 1**

1.3.1.1

	Hard gelatin capsules of size '2' with yellow opaque body imprinted with '100' and yellow opaque cap imprinted with 'NMC' with black ink, filled with yellow to light yellow granular powder.	
	<b>4. CLINICAL PARTICULARS</b>	
	<b>4.1. Therapeutic indications</b>	
	<b>MACRIXITIR</b> is indicated for the treatment and prevention of recurrence of uncomplicated lower urinary tract infections e.g. pyelonephritis, pyelitis and cystitis.  It is not indicated for the treatment of associated renal, cortical or perinephric abscesses.	
	<b>4.2. Posology and method of administration</b>	
	<b>Adults</b>  <b>Acute urinary tract infections:</b> 50 mg to 100 mg four times a day, with meals and at bedtime.  <b>To prevent recurrences:</b> 50 mg to 100 mg per day  <b>MACRIXITIR</b> may be given with food or milk to further minimise gastric upset. Therapy should be discontinued for at least one week and for at least 3 days after sterility of the urine is obtained. Continued infection indicates need for re-evaluation. Nitrofurantoin is highly soluble in urine, to which it may impart a brown colour.	
	<b>SPECIAL POPULATION</b>  <b>Paediatric patients:</b>  <b>Acute urinary tract infections:</b> Should be calculated on the basis of 5 to 7 mg/kg of body mass per 24 hours to be given in divided doses four times a day (contraindicated for children under one month)	



**Applicant:** Aurogen South Africa (Pty) Ltd

**Product Name:** MACRIXITIR

**Dosage form and strength:** **HARD GELATIN CAPSULE**, each capsule contains 50 mg and 100 mg Nitrofurantoin

**MODULE 1**

1.3.1.1

	To prevent recurrences: 1 mg/kg/day for long-term therapy.	
	<p><b>Method of administration</b></p> <p><b>MACRIXITIR</b> is administered orally.</p>	
	<b>4.3. Contraindications</b>	
	<p><b>MACRIXITIR</b> is contraindicated:</p> <ul style="list-style-type: none"> <li>• In patients with known sensitivity to nitrofurantoin microcrystals and any of the excipients of <b>[AUROFURAN]</b>.</li> <li>• In patients with a deficiency of glucose 6-phosphate dehydrogenase or nursing mothers of infants with this deficiency.</li> <li>• Anuria, oliguria and renal impairment are contraindications to therapy with <b>[AUROFURAN]</b>. Treatment of this type of patient carries an increased risk of toxicity because of impaired excretion of the Nitrofurantoin.</li> <li>• Pregnant women at term, as well as infants under one month of age, because of the possibility of haemolytic anaemia due to immature enzyme systems (glutathione instability).</li> </ul> <p><b>Acute porphyria</b></p> <ul style="list-style-type: none"> <li>• Patients suffering from renal impairment with an eGFR of less than 45mL/min.</li> </ul>	
	<b>4.4. Special warnings and precautions for use</b>	
	<ul style="list-style-type: none"> <li>• Prolonged use of <b>MACRIXITIR</b> is not recommended.</li> <li>• A course of therapy should not exceed 14 days and repeated courses should be separated by rest periods.</li> <li>• Pseudomonas is the organism most commonly implicated in superinfections in patients treated with <b>[AUROFURAN]</b>.</li> </ul>	

**Applicant:** Aurogen South Africa (Pty) Ltd

**Product Name:** MACRIXITIR

**Dosage form and strength:** **HARD GELATIN CAPSULE**, each capsule contains 50 mg and 100 mg Nitrofurantoin

**MODULE 1**

1.3.1.1

	<ul style="list-style-type: none"> <li>• Nitrofurantoin is not effective for the treatment of parenchymal infections of unilaterally nonfunctioning kidney. A surgical cause for infection should be excluded in recurrent or severe cases.</li> <li>• Nitrofurantoin may be used with caution as short-course therapy only for the treatment of uncomplicated lower urinary tract infection in individual cases with an eGFR between 30-44 mL/min to treat resistant pathogens, when the benefits are expected to outweigh the risks.</li> <li>• Since pre-existing conditions may mask adverse reactions, Nitrofurantoin should be used with caution in patients with pulmonary disease, hepatic dysfunction, neurological disorders, and allergic diathesis.</li> <li>• Peripheral neuropathy and susceptibility to peripheral neuropathy which may become severe or irreversible has occurred and may be life threatening. Therefore, treatment should be stopped at the first signs of neural involvement (paraesthesia).</li> <li>• Nitrofurantoin should be used in caution with patients with anaemia, diabetes mellitus, electrolyte imbalance, debilitating conditions and vitamin B (particularly folate) deficiency.</li> <li>• Cases of haemolytic anaemia of the primaquine sensitivity type have been induced by <b>[AUROFURAN]</b>.</li> <li>• Acute, subacute and chronic pulmonary reactions have been observed in patients treated with nitrofurantoin. If these reactions occur, nitrofurantoin should be discontinued immediately.</li> <li>• Patients with a history of asthma may experience acute asthmatic attacks.</li> </ul>	
--	---	--



**Applicant:** Aurogen South Africa (Pty) Ltd

**Product Name:** MACRIXITIR

**Dosage form and strength:** **HARD GELATIN CAPSULE**, each capsule contains 50 mg and 100 mg Nitrofurantoin

**MODULE 1**

1.3.1.1

	<ul style="list-style-type: none"> <li>• Chronic pulmonary reactions (including pulmonary fibrosis and diffuse interstitial pneumonitis) can develop insidiously, and may occur commonly in elderly patients. Close monitoring of the pulmonary condition of patients receiving long-term therapy is warranted (especially in the elderly).</li> <li>• Patient should be monitored closely for signs of hepatitis (particularly in long term use). Urine may be coloured yellow or brown after taking Nitrofurantoin. Patients on Nitrofurantoin are susceptible to false positive urinary glucose (if tested for reducing substances).</li> <li>• <b>MACRIXITIR</b> is not effective for the treatment of parenchymal infections of unilateral non-functioning kidney. A surgical cause for infection should be excluded in recurrent or sever cases.</li> <li>• The haemolysis appears to be linked to a glucose-6-phosphate dehydrogenase deficiency in the red blood cells of the affected patients. Any sign of haemolysis is an indication to discontinue the <b>[AUROFURAN]</b>.</li> <li>• Gastrointestinal reactions may be minimised by taking the medicine with food or milk, or by adjustment of dosage.</li> <li>• Discontinue treatment with Nitrofurantoin if otherwise unexplained pulmonary, hepatic, haematological or neurological syndromes occur.</li> </ul>	
	<p><b>4.5 Interaction with other medicines and other forms of interaction</b></p>	
	<ul style="list-style-type: none"> <li>• Probenecid or sulphinpyrazone may reduce the excretion of nitrofurantoin as in <b>MACRIXITIR</b> and should not be given concomitantly.</li> </ul>	



**Applicant:** Aurogen South Africa (Pty) Ltd

**Product Name:** MACRIXITIR

**Dosage form and strength:** **HARD GELATIN CAPSULE**, each capsule contains 50 mg and 100 mg Nitrofurantoin

**MODULE 1**

1.3.1.1

	<ul style="list-style-type: none"> <li>• Increased absorption with food or medicines delaying gastric emptying.</li> <li>• <b>MACRIXITIR</b> decreased absorption with magnesium trisilicate.</li> <li>• <b>MACRIXITIR</b> decreased anti-bacterial activity by carbonic anhydrase inhibitors and urine alkalisation.</li> <li>• Anti-bacterial antagonism by quinolone anti-infectives.</li> <li>• <b>MACRIXITIR</b> Interference with some tests for glucose in urine.</li> <li>• As Nitrofurantoin as in <b>MACRIXITIR</b> belongs to the group of Antibacterials, it will have the following interactions:</li> <li>• Typhoid Vaccine (oral): Antibacterials inactivate oral typhoid vaccine and certain laboratory tests.</li> </ul>	
	<p><b>4.5. Fertility, pregnancy and lactation</b></p> <p><b><u>Pregnancy</u></b></p> <p>Data in pregnant women indicate no teratogenicity or fetal/ neonatal toxicity. Animal studies do not show reproductive toxicity as clinically relevant doses. Therefore, <b>MACRIXITIR</b> can be used during pregnancy, except in pregnant women at term, as well as infants under one month of age, because of the possibility of haemolytic anaemia due to immature enzyme systems (glutathione instability).</p>	
	<p><b><u>Breastfeeding</u></b></p> <p><b>MACRIXITIR</b> is excreted in breast milk. <b>MACRIXITIR</b> can be used during breastfeeding, but it is contraindicated in those patients with a deficiency of glucose 6-phospahte dehydrogenase or nursing mothers of infants with this deficiency</p>	

**Applicant:** Aurogen South Africa (Pty) Ltd

**Product Name:** MACRIXITIR

**Dosage form and strength:** **HARD GELATIN CAPSULE**, each capsule contains 50 mg and 100 mg Nitrofurantoin

**MODULE 1**

1.3.1.1

	<p><b>4.6. Effects on ability to drive and use machines</b></p> <p>Nitrofurantoin can cause dizziness and drowsiness. Patient should be advised not to drive or operate machines until the symptoms disappear.</p>															
	<p><b>4.7. Undesirable effects</b></p> <p>A tabulated list of undesirable effects is outlined below:</p> <p>The undesirable effects are listed according to organ systems and following frequencies: Rare (<math>\geq 1/10,000</math> to <math>&lt; 1/1,000</math>)</p> <p>Not known (cannot be estimated from the available data).</p>															
	<p><b>a. <u>Tabulated list of adverse reactions</u></b></p> <p>Reported adverse reactions for nitrofurantoin are listed below according to organ systems.</p> <table border="1" data-bbox="316 1167 1136 1886"> <thead> <tr> <th>System organ class</th> <th>Frequency</th> </tr> </thead> <tbody> <tr> <td colspan="2"><b>Infections and infestations</b></td> </tr> <tr> <td>Superinfections by fungi or resistant organisms such as Pseudomonas. However, these are limited to the genitourinary tract.</td> <td>Frequency unknown</td> </tr> <tr> <td colspan="2"><b>Blood and Lymphatic system disorders</b></td> </tr> <tr> <td>Aplastic anemia</td> <td>Frequent</td> </tr> <tr> <td>Agranulocytosis, leucopenia, granulocytopenia, haemolytic anemia, thrombocytopenia, glucose -6-phosphate dehydrogenase deficiency anemia, megaloblastic anemia and eosinophilia.</td> <td>Frequency unknown</td> </tr> <tr> <td colspan="2"><b>Immune system disorders</b></td> </tr> </tbody> </table>	System organ class	Frequency	<b>Infections and infestations</b>		Superinfections by fungi or resistant organisms such as Pseudomonas. However, these are limited to the genitourinary tract.	Frequency unknown	<b>Blood and Lymphatic system disorders</b>		Aplastic anemia	Frequent	Agranulocytosis, leucopenia, granulocytopenia, haemolytic anemia, thrombocytopenia, glucose -6-phosphate dehydrogenase deficiency anemia, megaloblastic anemia and eosinophilia.	Frequency unknown	<b>Immune system disorders</b>		
System organ class	Frequency															
<b>Infections and infestations</b>																
Superinfections by fungi or resistant organisms such as Pseudomonas. However, these are limited to the genitourinary tract.	Frequency unknown															
<b>Blood and Lymphatic system disorders</b>																
Aplastic anemia	Frequent															
Agranulocytosis, leucopenia, granulocytopenia, haemolytic anemia, thrombocytopenia, glucose -6-phosphate dehydrogenase deficiency anemia, megaloblastic anemia and eosinophilia.	Frequency unknown															
<b>Immune system disorders</b>																



**Applicant:** Aurogen South Africa (Pty) Ltd

**Product Name:** MACRIXITIR

**Dosage form and strength:** **HARD GELATIN CAPSULE**, each capsule contains 50 mg and 100 mg Nitrofurantoin

**MODULE 1**

1.3.1.1

Allergic skin reactions, Angioneurotic oedema and anaphylaxis.	Frequency unknown
<b>Psychiatric disorders</b>	
Depression, euphoria, confusion, psychotic reactions.	Frequency unknown
<b>Nervous system disorders</b>	
Peripheral neuropathy including optic neuritis (sensory as well as motor involvement), nystagmus, vertigo, dizziness, headache and drowsiness. Benign intracranial hypertension.	Frequency unknown
<b>Cardiac disorders</b>	
Collapse and cyanosis.	Frequent
<b>Respiratory, thoracic and mediastinal disorders</b>	
Acute pulmonary reactions, Subacute pulmonary reactions*, Chronic pulmonary reactions, Cough, Dyspnoea, Pulmonary fibrosis; possible association with lupus-erythematosus-like syndrome.	Frequency unknown
<b>Gastrointestinal disorders</b>	
Sialadenitis, Pancreatitis, Nausea, Anorexia, Emesis, Abdominal pain and Diarrhoea.	Frequency unknown
<b>Hepatobiliary disorders</b>	
Cholestatic jaundice, Chronic active hepatitis (fatalities have been reported), Hepatic necrosis, autoimmune hepatitis.	Frequency unknown
<b>Skin and subcutaneous tissue disorders</b>	



**Applicant:** Aurogen South Africa (Pty) Ltd

**Product Name:** MACRIXITIR

**Dosage form and strength:** **HARD GELATIN CAPSULE**, each capsule contains 50 mg and 100 mg Nitrofurantoin

**MODULE 1**

1.3.1.1

<p>Transient alopecia</p> <p>Exfoliative dermatitis and erythema multiforme (including Stevens-Johnson Syndrome), maculopapular, erythematous or eczematous eruptions, urticaria, rash, and pruritus. Lupus-like syndrome associated with pulmonary reaction.</p> <p>Medicine Rash With Eosinophilia And Systemic Symptoms (DRESS syndrome), cutaneous vasculitis.</p>	<p>Frequency unknown</p>
<p><b>Renal and urinary disorders</b></p>	
<p>Yellow or brown discoloration of urine, interstitial nephritis.</p>	<p>Frequency unknown</p>
<p><b>General disorders and administration site conditions</b></p>	
<p>Asthenia, fever, chills, fever and arthralgia.</p>	<p>Frequency unknown</p>
<p><b>Investigations</b></p>	
<p>False positive urinary glucose test results</p>	<p>Frequency unknown</p>
<p>Acute pulmonary reactions usually occur within the first week of treatment and are reversible with cessation of therapy. Acute pulmonary reactions are commonly manifested by fever, chills, cough, chest pain, dyspnoea, pulmonary infiltration with consolidation or pleural effusion on chest x-ray, and eosinophilia. In subacute pulmonary reactions, fever and eosinophilia occur less often than in the acute form. Chronic pulmonary reactions occur rarely in patients who have received continuous therapy for six months or longer and are more common in elderly patients. Changes in ECG have occurred, associated with pulmonary reactions.</p>	



**Applicant:** Aurogen South Africa (Pty) Ltd

**Product Name:** MACRIXITIR

**Dosage form and strength:** **HARD GELATIN CAPSULE**, each capsule contains 50 mg and 100 mg Nitrofurantoin

**MODULE 1**

1.3.1.1

	<p><b>f. Reporting of suspected adverse reactions</b></p> <p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to SAHPRA via The '6.04 Adverse Drug Reactions Reporting Form'. Found under SAHPRA's publications: <a href="https://www.sahpra.org.za/Publications/Index/8">https://www.sahpra.org.za/Publications/Index/8</a></p>	
	<p><b>4.9 Overdose</b></p> <p>Symptoms and signs of overdose include gastric irritation, nausea and vomiting. Treatment is symptomatic and supportive.(see section 4.7)</p>	
	<p><b>5. PHARMACOLOGICAL PROPERTIES</b></p>	
	<p><b>5.1. Pharmacodynamic properties</b></p>	
	<p>A 18.5 Urinary tract antiseptics</p> <p>Pharmacotherapeutic group: antimicrobials for systemic use, Nitrofurantoin derivative.</p> <p>ATC code: J01XE01.</p>	
	<p>Mechanism of action</p> <p>Nitrofurantoin is an antibacterial medicine for specific urinary tract infections. Nitrofurantoin is a broad spectrum antibacterial medicine, active against the majority of urinary pathogens. The wide range of organisms sensitive to the bactericidal activity include:</p> <p><i>Escherichia coli</i></p> <p><i>Enterococcus Faecalis</i></p> <p><i>Klebsiella Species</i></p> <p><i>Enterobacter Species</i></p>	



**Applicant:** Aurogen South Africa (Pty) Ltd

**Product Name:** MACRIXITIR

**Dosage form and strength:** **HARD GELATIN CAPSULE**, each capsule contains 50 mg and 100 mg Nitrofurantoin

**MODULE 1**

1.3.1.1

	<p><i>Staphylococcus Species e.g. S. Aureus, S. Saprophyticus, S. Epidermidis Citrobacter Species</i></p> <p>Clinically most common urinary pathogens are sensitive to nitrofurantoin. Most strains of <i>Proteus</i> and <i>Serratia</i> are resistant. All <i>Pseudomonas</i> strains are resistant.</p>	
	<p><b>5.2. Pharmacokinetic properties</b></p>	
	<p>The nitrofurantoin macro crystals are specially formulated. The controlled crystal size is designed to control the speed of absorption and thus reduce the incidence of nausea. Clinical and animal studies indicate that Nitrofurantoin therapy decreases the likelihood of nausea in patients who might experience these symptoms on Nitrofurantoin therapy. This special formulation of Nitrofurantoin had not caused any decrease in antibacterial efficacy.</p> <p><b>Absorption</b></p> <p>Orally administered nitrofurantoin is rapidly and completely absorbed from the gastrointestinal tract and is rapidly excreted in the urine. Blood concentrations at therapeutic dosages are usually low.</p> <p><b>Elimination</b></p> <p>Anti-bacterial concentration are not achieved in plasma following ingestion of recommended doses because of rapid elimination, Maximum urinary excretion usually occurs 2-4 hours after administration of nitrofurantoin. Urinary medicine dose recoveries of about 40-45% are obtained. It has an elimination half-life of about 30 minutes.</p>	
	<p><b>5.3 Preclinical safety data</b></p> <p><b>Not applicable</b></p>	



**Applicant:** Aurogen South Africa (Pty) Ltd

**Product Name:** MACRIXITIR

**Dosage form and strength:** **HARD GELATIN CAPSULE**, each capsule contains 50 mg and 100 mg Nitrofurantoin

**MODULE 1**

1.3.1.1

	<b>Environmental Risk Assessment</b>	
	<b>Not Applicable</b>	
	<b>6. PHARMACEUTICAL PARTICULARS</b>	
	<p><b>6.1. List of excipients</b></p> <p><u>Capsules content:</u></p> <p>Nitrofurantoin</p> <p>Cellulose microcrystalline (Grade 101)</p> <p>Croscarmellose sodium (Ac-Di-Sol)</p> <p>Magnesium stearate (Ligamed MF-2-V)</p> <p><u>Capsules shell:</u></p> <p>Iron oxide yellow (E172)</p> <p>Titanium dioxide (E171)</p> <p>Gelatin</p> <p>Purified water</p> <p><u>Composition of the ink:</u></p> <p>Shellac</p> <p>Dehydrated Alcohol</p> <p>Isopropyl alcohol</p> <p>Butyl alcohol</p> <p>Propylene glycol</p> <p>Strong Ammonia solution</p> <p>Black Iron Oxide</p> <p>Potassium hydroxide</p> <p>Purified water</p>	
	<p><b>6.2. Incompatibilities</b></p> <p>Not applicable</p>	



**Applicant:** Aurogen South Africa (Pty) Ltd

**Product Name:** MACRIXITIR

**Dosage form and strength:** **HARD GELATIN CAPSULE**, each capsule contains 50 mg and 100 mg Nitrofurantoin

**MODULE 1**

1.3.1.1

<p><b>6.3. Shelf life</b></p> <p>24 months</p>		
<p><b>6.4. Special precautions for storage</b></p> <p>The capsules should be stored in light-resistant and preferably, moisture-proof containers.</p> <p>Store at or below 25°C.</p> <p>KEEP OUT OF REACH OF CHILDREN.</p>		
<p><b>6.5. Nature and contents of container</b></p>		
	<p>Blister Pack</p> <p>a) <u>Clear 250 micron PVC - Aluminium foil blister pack:</u> Blister pack comprises of clear thermoformable 250 micron PVC film as the forming film and printed 25 micron Aluminium foil as the lidding material.</p> <p><u>Pack Sizes:</u> 50's: Printed cardboard carton containing 5 blisters of 10 capsules each.</p> <p>b) <u>White Opaque 250 micron PVC film - Aluminium foil blister pack:</u></p> <p>Blister pack comprises of white opaque thermoformable rigid 250 micron PVC film as the forming film and printed 25 micron Aluminium foil as the lidding material.</p> <p><u>Pack Sizes:</u> 50's: Printed cardboard carton containing 5 blisters of 10 capsules each.</p> <p><u>HDPE Container Pack:</u></p>	



**Applicant:** Aurogen South Africa (Pty) Ltd

**Product Name:** MACRITIR

**Dosage form and strength:** **HARD GELATIN CAPSULE**, each capsule contains 50 mg and 100 mg Nitrofurantoin

**MODULE 1**

1.3.1.1

	<p><u>For Nitrofurantoin Capsules 50 mg:</u></p> <p>White opaque round 40 mL HDPE container with 33 mm neck finish closed with white opaque 33 mm – 400 polypropylene continuous thread closure with wad having Teknipler HS 123 induction sealing liner.</p> <p><u>Pack size:</u> 50's</p> <p><u>For Nitrofurantoin Capsules 100 mg:</u></p> <p>White opaque round 60 mL HDPE container with 33 mm neck finish closed with white opaque 33 mm – 400 polypropylene continuous thread closure with wad having Teknipler HS 123 induction sealing liner.</p> <p><u>Pack size:</u> 50's</p> <p>This Nitrofurantoin Capsules 50 mg and 100 mg HDPE bottles shall be further packed in pre-printed carton with a packaging leaflet.</p>	
	<p><b>6.6. Special precautions for disposal of a used medicine or waste materials derived from such medicine and other handling of the product</b></p> <p>No special requirements.</p>	
	<p><b>7. NAME AND BUSINESS ADDRESS OF THE HOLDER OF THE CERTIFICATE OF REGISTRATION</b></p> <p>AUROGEN SA (Pty) Ltd Woodhill Office Park, Building 1, First Floor 53 Phillip Engelbrecht Avenue Meyersdal, Ext. 12, 1448 Johannesburg South Africa</p>	
	<p><b>8. REGISTRATION NUMBER</b></p>	



**Applicant:** Aurogen South Africa (Pty) Ltd

**Product Name:** MACRIXITIR

**Dosage form and strength:** **HARD GELATIN CAPSULE**, each capsule contains 50 mg and 100 mg Nitrofurantoin

**MODULE 1**

1.3.1.1

	<b>MACRIXITIR 50</b> 55/18.5/0211.207 <b>MACRIXITIR 100</b> 55/18.5/0212.208	
	<b>9. DATE OF FIRST AUTHORISATION</b>  01 FEBRUARY 2022	
	<b>10. DATE OF REVISION OF TEXT</b>	

